Spyre Therapeutics share price today

Spyre Therapeutics, Inc.'s share price was $99.04 at the close on 4 November 2026. It has been rising for 39 weeks. That is 33.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $23 and $106, and at that close it sat 91% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Spyre Therapeutics, Inc. is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 5 weeks running.

Over the last 10 years the share price moved −6% while the S&P 500 moved +261%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 2 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Spyre Therapeutics, Inc. pays no dividend. In the last 8 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Spyre Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Spyre Therapeutics, Inc. posted a net loss of $217 M in the Jun 2023 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY23 year was a loss of $94.9 M. That loss is 31,552.5% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost $22.3 M. 8 of the last 8 reported quarters were loss-making.

Read this profit with care: at −$217 M it is bigger than the quarter's whole revenue of $688 K. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −2,588.4% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

Spyre Therapeutics, Inc. reported $688 K of revenue in the Jun 2023 quarter, +10.1% on the same quarter a year earlier. Over 2 years it has grown −78.3% a year on average. The last full year, FY23, came in at $886 K. The last four reported quarters add to $1.2 M.

Revenue is everything the company billed its customers in the period.

FY23 revenue was $886 K, −62.0% on the year before.

Recent pace: the last four quarters grew −64.6% on average, against −78.3% a year over the longer run, so this year is growing faster than its own long-run rate.

Spyre Therapeutics, Inc.'s sales have fallen to very little: FY23 revenue was $886 K, against $18.7 M in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover.

Spyre Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY23 its operations used $99.9 M of cash, against −$94.9 M of profit. After null of spending on assets, free cash was −$99.9 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Spyre Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $611 K on assets over the last 2 years. Averaged over those years that is 34.5% of FY23 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $611 K over the last 2 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

Spyre Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Spyre Therapeutics, Inc. at 10,446.4× its FY23 revenue of $886 K. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Spyre Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 0 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Spyre Therapeutics, Inc. earned a ROE of −52% in FY23. That is up from a low of −167% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −27%, a number that says nothing useful about the business.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Spyre Therapeutics, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.07 in FY21 to 0.09 in FY22. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

14.3% of Spyre Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 8.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Spyre Therapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

55.8 out of 100, rank 9 of 30 in Biotechnology, with 56% of the evidence available.

Spyre Therapeutics, Inc. scores 55.8 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 9. Some evidence is missing, so the score is pulled toward the middle on purpose.

The four parts add up to the total exactly: 23.3 + 8.6 + 10.9 + 13 = 55.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Spyre Therapeutics ranks 9 of 30 Biotechnology companies on the 4-Factor Sector Score, with 55.8 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Biotechnology, all 30 compared on one page.

Spyre Therapeutics is the 27th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Caris Life Sciences, Inc., Madrigal Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. Just below it: Krystal Biotech, Inc., Crinetics Pharmaceuticals, Inc. and Cytokinetics, Incorporated.

Biotechnology companies close in size

24. Caris Life Sciences, Inc. $9.4 billion
25. Madrigal Pharmaceuticals, Inc. $9.3 billion
26. Protagonist Therapeutics, Inc. $9.3 billion
27. Spyre Therapeutics, Inc. $9.3 billion
28. Krystal Biotech, Inc. $9.2 billion
29. Crinetics Pharmaceuticals, Inc. $9 billion
30. Cytokinetics, Incorporated $8.8 billion

All 211 Biotechnology companies, largest first

Companies close in size in other industries

960. Brixmor Property Group Inc. $9.3 billion · REIT - Retail
961. Core & Main, Inc. $9.3 billion · Industrial Distribution
962. Spyre Therapeutics, Inc. $9.3 billion
963. Krystal Biotech, Inc. $9.2 billion · Biotechnology
964. Viasat, Inc. $9.2 billion · Communication Equipment

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.